Nicole Daley

Ms. Daley’s recent client representations include the following:

IPOs and Capital Markets Transactions

• Deciphera Pharmaceuticals in its $175 million follow-on public offering.
• Karuna Therapeutics in its $100 million initial public offering and a $250 million follow-on offering.
• BioDelivery Sciences International in its $60 million follow-on public offering.
• Alnylam Pharmaceuticals in a $387.5 million follow-on public offering.

Private Financings

• Beta Bionics in its $63 million Series B2 financing.
• Karuna Therapeutics in its $82 million Series B financing.
• Thrive Earlier Detection Corp. in its $110 million Series A financing.

Joint Ventures, M&A and Collaborations

• Alnylam Pharmaceuticals in a $100 million equity financing closed in connection with its $2 billion strategic financing collaboration with Blackstone.
• CRISPR Therapeutics in a series of transactions by which CRISPR acquired 100% of the partnership interests of Casebia Therapeutics.
• BeiGene in its $2.7 billion share sale as part of a global strategic collaboration with Amgen.
• BlueRock Therapeutics on its agreement to be fully acquired by Bayer AG for up to $1 billion.
• Ultragenyx Pharmaceutical Inc. on its partnership with GeneTx Biotherapeutics LLC to develop GeneTx’s GTX-102.
• Arvinas, Inc. in its collaboration with Bayer to jointly launch a new company to leverage Arvinas’ PROTAC technology for agricultural applications.
• Alnylam Pharmaceuticals in a $400 million equity financing closed in connection with Alnylam’s collaboration with Regeneron Pharmaceuticals.
• A global provider of digital communication services, in its $640 million going-private transaction.*
• A public business software company in its $600 million stock-for-stock acquisition by another global public company in the electronic business solutions industry.*
• A global provider of telecom products and services, in its $272 million sale of assets involving operations and employees in over 20 countries.*

*Denotes experience prior to joining Goodwin.